VERTEX PHARMACEUTICALS INC (VRTX) Fundamental Analysis & Valuation

NASDAQ:VRTX • US92532F1003

469.34 USD
-8.79 (-1.84%)
At close: Mar 13, 2026
470.28 USD
+0.94 (+0.2%)
After Hours: 3/13/2026, 5:20:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VRTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Overall VRTX gets a fundamental rating of 7 out of 10. We evaluated VRTX against 519 industry peers in the Biotechnology industry. VRTX gets an excellent profitability rating and is at the same time showing great financial health properties. VRTX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make VRTX suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

7

1. VRTX Profitability Analysis

1.1 Basic Checks

  • In the past year VRTX was profitable.
  • VRTX had a positive operating cash flow in the past year.
  • Of the past 5 years VRTX 4 years were profitable.
  • VRTX had a positive operating cash flow in 4 of the past 5 years.
VRTX Yearly Net Income VS EBIT VS OCF VS FCFVRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • VRTX's Return On Assets of 15.42% is amongst the best of the industry. VRTX outperforms 95.57% of its industry peers.
  • VRTX has a better Return On Equity (21.18%) than 95.76% of its industry peers.
  • VRTX has a Return On Invested Capital of 16.99%. This is amongst the best in the industry. VRTX outperforms 97.30% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for VRTX is in line with the industry average of 19.44%.
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROIC 16.99%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)17.75%
ROIC(5y)19.09%
VRTX Yearly ROA, ROE, ROICVRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • The Profit Margin of VRTX (32.94%) is better than 96.53% of its industry peers.
  • VRTX's Profit Margin has declined in the last couple of years.
  • The Operating Margin of VRTX (39.04%) is better than 97.88% of its industry peers.
  • VRTX's Operating Margin has declined in the last couple of years.
  • VRTX has a better Gross Margin (86.24%) than 88.25% of its industry peers.
  • In the last couple of years the Gross Margin of VRTX has remained more or less at the same level.
Industry RankSector Rank
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
VRTX Yearly Profit, Operating, Gross MarginsVRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. VRTX Health Analysis

2.1 Basic Checks

  • VRTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, VRTX has less shares outstanding
  • VRTX has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for VRTX has been reduced compared to a year ago.
VRTX Yearly Shares OutstandingVRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VRTX Yearly Total Debt VS Total AssetsVRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 12.60 indicates that VRTX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of VRTX (12.60) is better than 84.20% of its industry peers.
  • The Debt to FCF ratio of VRTX is 0.03, which is an excellent value as it means it would take VRTX, only 0.03 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of VRTX (0.03) is better than 96.34% of its industry peers.
  • VRTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.01, VRTX perfoms like the industry average, outperforming 47.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 12.6
ROIC/WACC1.91
WACC8.91%
VRTX Yearly LT Debt VS Equity VS FCFVRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.90 indicates that VRTX has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.90, VRTX is not doing good in the industry: 65.13% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.46 indicates that VRTX has no problem at all paying its short term obligations.
  • VRTX's Quick ratio of 2.46 is on the low side compared to the rest of the industry. VRTX is outperformed by 68.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.46
VRTX Yearly Current Assets VS Current LiabilitesVRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. VRTX Growth Analysis

3.1 Past

  • VRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
  • The Earnings Per Share has been growing by 12.27% on average over the past years. This is quite good.
  • The Revenue has grown by 8.90% in the past year. This is quite good.
  • VRTX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.10% yearly.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%

3.2 Future

  • VRTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.36% yearly.
  • The Revenue is expected to grow by 10.31% on average over the next years. This is quite good.
EPS Next Y5.3%
EPS Next 2Y9.43%
EPS Next 3Y10.17%
EPS Next 5Y12.36%
Revenue Next Year8.79%
Revenue Next 2Y9.46%
Revenue Next 3Y10.13%
Revenue Next 5Y10.31%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
VRTX Yearly Revenue VS EstimatesVRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VRTX Yearly EPS VS EstimatesVRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

5

4. VRTX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 25.49, the valuation of VRTX can be described as expensive.
  • VRTX's Price/Earnings ratio is rather cheap when compared to the industry. VRTX is cheaper than 92.68% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.71, VRTX is valued at the same level.
  • VRTX is valuated rather expensively with a Price/Forward Earnings ratio of 24.21.
  • Based on the Price/Forward Earnings ratio, VRTX is valued cheaply inside the industry as 93.06% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, VRTX is valued at the same level.
Industry RankSector Rank
PE 25.49
Fwd PE 24.21
VRTX Price Earnings VS Forward Price EarningsVRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 92.87% of the companies in the same industry are more expensive than VRTX, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of VRTX indicates a rather cheap valuation: VRTX is cheaper than 93.83% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 37.33
EV/EBITDA 22.86
VRTX Per share dataVRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • VRTX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.81
PEG (5Y)2.08
EPS Next 2Y9.43%
EPS Next 3Y10.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRTX Dividend Analysis

5.1 Amount

  • No dividends for VRTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VRTX Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

NASDAQ:VRTX (3/13/2026, 5:20:02 PM)

After market: 470.28 +0.94 (+0.2%)

469.34

-8.79 (-1.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.75%
Inst Owner Change-0.9%
Ins Owners0.15%
Ins Owner Change1.31%
Market Cap119.23B
Revenue(TTM)12.00B
Net Income(TTM)3.95B
Analysts81.03
Price Target540.92 (15.25%)
Short Float %1.76%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.17%
Min EPS beat(2)-2.79%
Max EPS beat(2)3.12%
EPS beat(4)2
Avg EPS beat(4)-0.85%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)4
Avg EPS beat(8)-64.44%
EPS beat(12)6
Avg EPS beat(12)-43.04%
EPS beat(16)9
Avg EPS beat(16)-31.46%
Revenue beat(2)0
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-1.51%
Max Revenue beat(2)-1.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)0.06%
Revenue beat(8)3
Avg Revenue beat(8)-0.66%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-0.51%
PT rev (1m)1.58%
PT rev (3m)8.84%
EPS NQ rev (1m)-9.25%
EPS NQ rev (3m)-9.31%
EPS NY rev (1m)-4.91%
EPS NY rev (3m)-4.92%
Revenue NQ rev (1m)-1.94%
Revenue NQ rev (3m)-1.76%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE 25.49
Fwd PE 24.21
P/S 9.93
P/FCF 37.33
P/OCF 32.83
P/B 6.39
P/tB 6.95
EV/EBITDA 22.86
EPS(TTM)18.41
EY3.92%
EPS(NY)19.39
Fwd EY4.13%
FCF(TTM)12.57
FCFY2.68%
OCF(TTM)14.3
OCFY3.05%
SpS47.24
BVpS73.48
TBVpS67.53
PEG (NY)4.81
PEG (5Y)2.08
Graham Number174.46
Profitability
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROCE 21.51%
ROIC 16.99%
ROICexc 27.12%
ROICexgc 30.49%
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
FCFM 26.61%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)17.75%
ROIC(5y)19.09%
ROICexc(3y)32.46%
ROICexc(5y)46.28%
ROICexgc(3y)40.07%
ROICexgc(5y)66.49%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-36.41%
ROICexgc growth 5Y-24.43%
ROICexc growth 3Y-28.98%
ROICexc growth 5Y-17.32%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 208.58%
Cap/Sales 3.65%
Interest Coverage 377.85
Cash Conversion 74.18%
Profit Quality 80.79%
Current Ratio 2.9
Quick Ratio 2.46
Altman-Z 12.6
F-Score7
WACC8.91%
ROIC/WACC1.91
Cap/Depr(3y)195.12%
Cap/Depr(5y)182.1%
Cap/Sales(3y)3.56%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y5.3%
EPS Next 2Y9.43%
EPS Next 3Y10.17%
EPS Next 5Y12.36%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year8.79%
Revenue Next 2Y9.46%
Revenue Next 3Y10.13%
Revenue Next 5Y10.31%
EBIT growth 1Y6.59%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year6.57%
EBIT Next 3Y12.66%
EBIT Next 5Y11.43%
FCF growth 1Y426.56%
FCF growth 3Y-6.64%
FCF growth 5Y1.3%
OCF growth 1Y837.19%
OCF growth 3Y-4.2%
OCF growth 5Y2.22%

VERTEX PHARMACEUTICALS INC / VRTX FAQ

Can you provide the ChartMill fundamental rating for VERTEX PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 7 / 10 to VRTX.


What is the valuation status for VRTX stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VRTX). This can be considered as Fairly Valued.


Can you provide the profitability details for VERTEX PHARMACEUTICALS INC?

VERTEX PHARMACEUTICALS INC (VRTX) has a profitability rating of 7 / 10.


What is the valuation of VERTEX PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VRTX) is 25.49 and the Price/Book (PB) ratio is 6.39.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VRTX) is 8 / 10.